Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents Meeting Abstract


Authors: Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; Abdel-Wahab, O. I.; Klimek, V. M.
Abstract Title: Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837600287
PROVIDER: wos
Notes: Meeting Abstract: 233 -- Source: Wos
MSK Authors
  1. Virginia Klimek
    109 Klimek
  2. Eytan Moshe Stein
    122 Stein
  3. Martin Stuart Tallman
    443 Tallman
  4. Jae Hong Park
    147 Park
  5. Stephen Shiu-Wah Chung
    58 Chung
  6. Raajit Kumar Rampal
    139 Rampal
  7. Filiz   Sen
    10 Sen
  8. Justin   Taylor
    22 Taylor